Fentanyl Transdermal Patch and Schisandra Sphenanthera: Interaction Details
- Fentanyl Transdermal Patch
- DuragesicAbstralSubsys +3 more
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Fentanyl Transdermal Patch and Schisandra Sphenanthera interaction:
Schisandra Sphenanthera
We don't have a drug information page for Schisandra Sphenanthera yet. Have a question about Schisandra Sphenanthera? Ask a pharmacist, free →
Fentanyl Transdermal Patch
- Duragesic
- Abstral
- Subsys
- Ionsys
- Actiq
- Fentora
What Happens When You Take Fentanyl Transdermal Patch With Schisandra Sphenanthera
What can happen when they are taken together (rated Major)
Increased fentaNYL exposure and an increased risk of prolonged effects
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
When fentaNYL is taken together with a , fentaNYL can rise, which may intensify or prolong opioid effects. This is especially true if the inhibitor is introduced after the patient has already reached a stable fentaNYL dose.
Where combined use cannot be avoided, a lower fentaNYL dosage should be considered until effects stabilize, and patients should be assessed often for and . The reverse situation arises when a CYP3A4 inhibitor is stopped: as its inhibitory effect wanes, fentaNYL plasma concentrations fall, which can reduce opioid or precipitate a withdrawal syndrome in patients who have become physically dependent on fentaNYL. In that case, consider raising the fentaNYL dosage until effects are stable, and monitor for signs of opioid withdrawal.4231
The Fentanyl Transdermal Patch and Schisandra Sphenanthera Interaction, Explained
Schisandra sphenanthera is an herbal supplement that can slow down , a liver enzyme your body uses to break down fentanyl. When that enzyme is slowed, more fentanyl can stay in your body than your doctor planned for. That can mean stronger or longer-lasting effects, like heavy sleepiness, slowed breathing, or confusion.
The risk is greatest if you start the supplement while already on a steady patch dose. Stopping it later can also change how the patch works. Please don't start or stop either one on your own. Tell your pharmacist or doctor about the supplement, and they can adjust your dose and watch you more closely to keep you safe.
Mechanism: Schisandra sphenanthera inhibits , the primary pathway for fentanyl . This increases fentanyl exposure (higher ) and risk of prolonged effects, including and . Fentanyl is active as given, so raises its effect.
- Evidence: established; severity major; onset unspecified.
- Highest risk: added after a stable fentanyl dose.
- Management: if is necessary, consider fentanyl dose reduction until stable effects are achieved, and monitor frequently for respiratory depression and sedation.
- On discontinuation: fentanyl levels fall, which may cause reduced or withdrawal in dependent patients. Consider increasing the dose until effects stabilize and monitor for withdrawal.
See the 8 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Fentanyl Transdermal Patch and Schisandra Sphenanthera Interact
The likely mechanism
of -mediated of fentaNYL
How to Manage the Fentanyl Transdermal Patch and Schisandra Sphenanthera Interaction
Your care team can manage this by tailoring your fentanyl dose and monitoring you closely.
- If you need to use both, your doctor may lower your fentanyl dose until your response is stable.
- You may be checked more often for slowed breathing and sleepiness.
- If the supplement is stopped later, fentanyl levels can drop, so your dose may need to be increased and you may be watched for withdrawal signs.
Keep taking your medicines as prescribed, and tell your pharmacist or prescriber about any supplement before starting or stopping it.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Fentanyl Transdermal Patch or Schisandra Sphenanthera need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
5 reports from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Prescribing information: DIFLUCAN oral tablets, suspension, fluconazole oral tablets, suspension
A single fatal case of a possible fentaNYL-fluconazole interaction has been reported, and the author concluded that the patient died of fentaNYL intoxication. In addition, a randomized crossover study in 12 healthy volunteers showed that fluconazole significantly delayed the of fentaNYL. Increased fentaNYL concentrations may result in .6
-
Report 2 · Study title
Ritonavir's role in reducing fentanyl clearance and prolonging its half-life
Twelve healthy volunteers were given either placebo or oral ritonavir three times daily for 3 days, and fentaNYL 5 mcg/kg IV was administered after the second ritonavir dose on day 2. Naloxone was given before and together with the fentaNYL dose to prevent the sedative and respiratory depressant effects of fentaNYL.
One subject withdrew from the study before receiving fentaNYL. Among the 11 remaining participants, ritonavir reduced the plasma of fentaNYL by 67% (from 15.6 to 5.2 mL/min/kg).
Compared with placebo, the of fentaNYL rose from 9.4 hours to 20.1 hours after ritonavir, and the area under the concentration-time curve () rose by 174% (from 6.6 to 18.1 ng/mL/hr). Ritonavir is considered likely to affect the elimination of transdermally administered fentaNYL in a similar way.5
-
Report 3 · Study title
Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl
In an open, randomized, crossover study, giving fluconazole with a single IV dose of fentaNYL lowered the mean plasma of fentaNYL by 16%. Twelve healthy volunteers received a single IV dose of fentaNYL 5 mcg/kg either alone (control phase) or 1 hour after the last fluconazole dose on day 2 (400 mg orally once daily on day 1, then 200 mg orally once daily on day 2).
Naloxone was administered before and with the fentaNYL dose to prevent sedative and respiratory depressant effects. All 12 subjects finished the study.
In the fluconazole phase, mean plasma clearance was 16% lower than in the control phase (range, -34% to 53%; p less than 0.05). The fentaNYL showed a nonsignificant increase (fluconazole phase, 7.7 +/- 2.3 nanograms (ng) x hr/mL vs control phase 6.1 +/- 1.1 ng x hr/mL), whereas the inactive norfentaNYL declined markedly (fluconazole phase, 0.8 +/- 0.7 ng x hr/mL vs control phase, 1.8 +/- 1.1 ng x hr/mL).
The ratio of norfentaNYL AUC to fentaNYL AUC was significantly lower in the fluconazole phase than in the control phase (AUC ratio, 0.1 +/- 0.1 vs 0.3 +/- 0.2). Mean of fentaNYL was similar in both phases. The altered fentaNYL clearance seemed to result from of -mediated N-dealkylation of fentaNYL to norfentaNYL.7
-
Report 4 · Study title
Possible fluconazole-fentanyl interaction-a case report
A 46-year-old man using transdermal fentaNYL died after concurrent treatment with fluconazole. He had oral pain from radiation therapy for tonsillar cancer and was treated with a fentaNYL 100 mcg/hr transdermal patch.
Over the following 1.5 months, the fentaNYL dose was raised to 150 mcg/hr. medications included morphine 10 mg orally once daily, diclofenac 50 mg orally 3 times daily, paracetamol 1000 mg orally 3 times daily, oxazepam 15 mg orally twice daily, zolpidem 5 mg orally nightly, nystatin (100,000 international units/mL) 4 times daily, metoclopramide 20 mg rectally 3 times daily, lidocaine oral spray, and lactulose.
Two weeks after the increase to fentaNYL 150 mcg/hr, he had a percutaneous gastrostomy because of worsening dysphagia. Eight days later he developed an oral fungal infection and was started on oral fluconazole 50 mg/day.
Three days after that, he died in his sleep. Forensic analysis found a toxic fentaNYL concentration (0.017 mcg/g), high concentrations of fluconazole (2.4 mcg/g), lidocaine (1.6 mcg/g), and metoclopramide (0.15 mcg/g), and a therapeutic zolpidem concentration.
No evidence of ethanol or drugs of abuse was found. The only autopsy findings were pulmonary congestion and brain edema. There was no indication of intentional overdose, and the coroner determined that the cause of death was and circulatory failure due to fentaNYL intoxication.8
-
Report 5 · Study title
Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl
In an open, randomized, crossover study, giving voriconazole with a single IV dose of fentaNYL raised the mean of fentaNYL 1.4-fold and lowered the mean plasma by 23%. Twelve healthy volunteers received a single IV dose of fentaNYL 5 mcg/kg either alone (control phase) or 1 hour after the last voriconazole dose on day 2 (400 mg orally twice daily on day 1, then 200 mg orally twice daily on day 2).
Naloxone was given before and with the fentaNYL dose to prevent sedative and respiratory depressant effects. All 12 subjects finished the study.
In the voriconazole phase, the mean fentaNYL AUC (0 to infinity) was 1.4-fold higher (range, 0.81- to 2.04-fold) and mean plasma clearance was 23% lower (range -22% to 48%) than in the control phase. Notably, the mean fentaNYL at 12 hr in the voriconazole phase equaled the concentration at 6 hr in the control phase.
Mean of fentaNYL again did not differ between phases. Nausea and vomiting occurred in 4 subjects during the voriconazole phase and in 2 subjects during the control phase. No additional naloxone doses were needed, and no other adverse events were reported.7
Fentanyl Transdermal Patch and Schisandra Sphenanthera: Common Questions
How serious is the Fentanyl Transdermal Patch and Schisandra Sphenanthera interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Fentanyl Transdermal Patch and Schisandra Sphenanthera interaction managed?
Your care team can manage this by tailoring your fentanyl dose and monitoring you closely. If you need to use both, your doctor may lower your fentanyl dose until your response is stable. You may be checked more often for slowed breathing and sleepiness. If the supplement is stopped later, fentanyl levels can drop, so your dose may need to be increased and you may be watched for withdrawal signs.… Management is individual — always follow your own care team's guidance.
Does taking Fentanyl Transdermal Patch and Schisandra Sphenanthera at different times of day help?
No. Taking them at different times of day does not prevent this one. Schisandra sphenanthera slows , an enzyme that breaks down fentanyl, so fentanyl can build up in the body. That change lasts while schisandra sphenanthera is being taken and can continue for a while after the last dose.
Your pharmacist or prescriber can tell you how they will manage it.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "established". Well documented — supported by controlled studies or strong clinical data.
Ask About the Fentanyl Transdermal Patch and Schisandra Sphenanthera Interaction
Ask in your own words about taking Fentanyl Transdermal Patch and Schisandra Sphenanthera together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (8)
- Product Information: DURAGESIC(R) transdermal system, fentanyl transdermal system. Janssen Pharmaceuticals Inc (per manufacturer), Titusville, NJ, 2018. DailyMed
- Product Information: ACTIQ(R) oral transmucosal lozenge, fentanyl citrate oral transmucosal lozenge. Teva Pharmaceuticals USA, Inc. (per FDA), Parsippany, NJ, 2023. DailyMed
- Product Information: Fentanyl citrate intravenous, intramuscular injection, fentanyl citrate intravenous, intramuscular injection. Hospira Inc (per FDA), Lake Forest, IL, 2023. DailyMed
- Product Information: FENTORA(R) buccal tablets, fentanyl citrate buccal tablets. Teva Pharmaceuticals USA Inc (per FDA), Parsippany, NJ, 2023.
- Olkkola KT, Palkama VJ, & Neuvonen PJ: Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 1999; 91:681-685. PubMed
- Product Information: DIFLUCAN(R) oral tablets, suspension, fluconazole oral tablets, suspension. Roerig (per FDA), New York, NY, 2023. DailyMed
- Saari TI, Laine K, Neuvonen M, et al: Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol 2008; 64(1):25-30. PubMed
- Hallberg P, Marten L, & Wadelius M: Possible fluconazole-fentanyl interaction-a case report. Eur J Clin Pharmacol 2006; 62(6):491-492. PubMed
Other Serious Interactions of Fentanyl Transdermal Patch and Schisandra Sphenanthera
Also serious with Schisandra Sphenanthera
Also serious with Fentanyl Transdermal Patch
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data. This interaction.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.